Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Cash from Financing Activities (2019 - 2026)

Nurix Therapeutics (NRIX) has disclosed Cash from Financing Activities for 8 consecutive years, with $20.0 million as the latest value for Q1 2026.

  • Quarterly Cash from Financing Activities rose 1256.08% to $20.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $257.1 million through Feb 2026, down 47.04% year-over-year, with the annual reading at $238.6 million for FY2025, 50.86% down from the prior year.
  • Cash from Financing Activities for Q1 2026 was $20.0 million at Nurix Therapeutics, down from $236.0 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $237.8 million in Q2 2024, with the low at -$135000.0 in Q4 2022.
  • Average Cash from Financing Activities over 5 years is $50.9 million, with a median of $1.5 million recorded in 2022.
  • The sharpest move saw Cash from Financing Activities tumbled 127.0% in 2022, then surged 2864485.71% in 2024.
  • Over 5 years, Cash from Financing Activities stood at -$135000.0 in 2022, then soared by 105.19% to $7000.0 in 2023, then soared by 2864485.71% to $200.5 million in 2024, then rose by 17.7% to $236.0 million in 2025, then plummeted by 91.54% to $20.0 million in 2026.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $20.0 million, $236.0 million, and $1.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.